Angiomammography for Breast Cancer Response Prediction
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Angiomammography for Breast Cancer Response Prediction?
The research suggests that neoadjuvant chemotherapy, which is part of the treatment, is becoming a standard approach for breast cancer and helps in avoiding more invasive surgeries. Imaging techniques, like those used in Angiomammography, are valuable for assessing how well the cancer responds to this chemotherapy, potentially allowing for more personalized and effective treatment plans.12345
How is neoadjuvant chemotherapy different from other breast cancer treatments?
What is the purpose of this trial?
The best prognostic factor following neoadjuvant chemotherapy is the pathological complete response (pCR). pCR is defined as the absence of invading cells in the breast and lymph nodes following neoadjuvant chemotherapy treatment. Since patients with pCR have a better prognosis than those without pCR, some studies have evaluated different methods to predict pCR early in treatment. Thus, patients who do not respond optimally to treatment could be identified early and changed treatment in order to maximize the chances of pCR and avoid the morbidity of poorly effective treatments. To do this, several modalities have been proposed, including MRI, mammography, ultrasound, positron emission tomography, elastography, and serial biopsies, but these techniques have shown predictive and sometimes expensive. Nevertheless, assessment of tumor response after cycle 2 has been suggested to be appropriate for the prediction of pCR.The main objective of this study is to compare the performance of two diagnostic modalities, namely CESM and MRI, in the evaluation of the response of a malignant breast tumor to neoadjuvant chemotherapy and the prediction of pCR. The radiological response will also be compared to the clinical response.
Eligibility Criteria
This trial is for women over 18 with breast cancer that hasn't spread far (no distant metastasis), measurable by examination. They must be undergoing neoadjuvant chemotherapy, possibly with additional targeted therapy. Exclusions include pregnancy, allergies to contrast dye, MRI contraindications, overt hyperthyroidism, and significant kidney failure.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Chemotherapy
Participants receive neoadjuvant chemotherapy to evaluate the response of a malignant breast tumor
Assessment
Prediction of pathological complete response (pCR) using angiomammography after cycle 2 of neoadjuvant chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Angiomammography
- Neoadjuvant Chemotherapy
Neoadjuvant Chemotherapy is already approved in European Union, United States, Canada, Japan, China for the following indications:
- Breast cancer
- Ovarian cancer
- Colorectal cancer
- Lung cancer
- Esophageal cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
- Lung cancer
- Esophageal cancer
- Stomach cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
- Lung cancer
- Esophageal cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
- Lung cancer
- Esophageal cancer
- Stomach cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
- Lung cancer
- Esophageal cancer
- Stomach cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
CHU de Quebec-Universite Laval
Lead Sponsor